<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850252</url>
  </required_header>
  <id_info>
    <org_study_id>Cytograft A-V</org_study_id>
    <secondary_id>R44HL064462-06</secondary_id>
    <nct_id>NCT00850252</nct_id>
  </id_info>
  <brief_title>Use of a Lifeline Graft in the A-V Shunt Model</brief_title>
  <official_title>Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytograft Tissue Engineering</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytograft Tissue Engineering</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of a completely autologous and completely
      biological tissue engineered blood vessel (TEBV) called Lifeline™ used as an arteriovenous
      fistula for dialysis access.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary purpose of this study will be to gain preliminary safety experience with Lifeline blood vessel as an arteriovenous fistula</measure>
    <time_frame>minimum 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary purpose of the study is to assess the efficacy of the Lifeline blood vessel used as hemodialysis access in ESRD patients</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>ESRD</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Lifeline blood vessel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lifeline</intervention_name>
    <description>Surgical arteriovenous fistula formation with the use of Lifeline blood vessel</description>
    <arm_group_label>Lifeline blood vessel</arm_group_label>
    <other_name>Tissue engineered blood vessel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed an informed consent

          -  Patients ≥ 21 years old

          -  Patients not candidates for a Brescia-Cimino A-V fistula (own vessels)

          -  Have an AV shunt or fistula that will likely fail within 12 months because of:

               -  Signs of clinical dysfunction: increment of venous pressure, limited site of
                  puncture, stenosis, aneurysm dilatations that cannot be surgically repaired or by
                  other media, or

               -  Previous angioplasty, or

               -  Previous thrombolysis

          -  Fall into category of ASA grade 2 or below (or UK equivalent)

          -  Are willing and able to comply with 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and 52 week
             follow up and able to comply with biannual follow up thereafter.

        Exclusion Criteria:

          -  A need for urgent surgery

          -  Penicillin allergy

          -  Patients with uncontrolled hypertension

          -  Morbid obesity (&gt; 300 lbs)

          -  Active systemic infection

          -  Contraindication for anticoagulation

          -  Coagulopathy

          -  Acute renal failure

          -  Connective tissue diseases (i.e. Marfan's syndrome)

          -  Pregnant or nursing

          -  Life expectancy &lt; 1 year

          -  Participation in another study involving an investigational device or new drug

          -  Other medical, social or psychological issues that, in the opinion of the principal
             investigator, preclude them from receiving the treatment and the
             procedures/evaluations of the post-operative follow up

          -  Inability or unwillingness to comply with the scheduled follow-up visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis M de la Fuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IADT, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lech Cierpka, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of General, Vascular and Transplant Surgery, Katowice, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Argentino de Diagnostico y Tratamiento</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Vascular and Transplant Surgery</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lifeline</keyword>
  <keyword>Tissue engineered blood vessel</keyword>
  <keyword>A-V shunt</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

